Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation.
Kana WatanabeRyota SaitoEisaku MiyauchiHiromi NagashimaAtsushi NakamuraShunichi SugawaraNobuyuki TanakaHiroshi TerasakiTatsuro FukuharaMakoto MaemondoPublished in: Cancers (2023)
Plasma EGFR mutation analysis was effective in predicting the effect of osimertinib treatment.